Leser‑Trélat Sign – Comprehensive Medical Guide

Overview

The Leser‑Trélat sign is a paraneoplastic dermatosis characterized by the sudden eruption of multiple, often pruritic, seborrheic‑keratosis‑like papules and nodules on the trunk and proximal limbs. It is not a disease itself but a skin manifestation that can herald an underlying internal malignancy, most commonly gastrointestinal adenocarcinomas.

Who it affects: The sign is seen almost exclusively in adults, typically between the ages of 50 and 70, because the associated cancers increase in incidence with age. It is slightly more common in men, reflecting the higher prevalence of gastrointestinal cancers in males.

Prevalence: Precise epidemiologic data are limited, but studies suggest that the Leser‑Trélat sign occurs in approximately 1–3 % of patients with internal malignancies and accounts for less than 0.5 % of all dermatology clinic visits.¹ Because it is rare and often under‑recognized, the true prevalence may be slightly higher.

Symptoms

The sign itself is a skin finding, but patients often experience associated symptoms that can help differentiate it from ordinary seborrheic keratoses.

Typical cutaneous findings

• Rapid onset: Development of dozens to hundreds of lesions over weeks to a few months.
• Appearance: Rough, “stuck‑on” papules or nodules, ranging from 1 mm to >2 cm, often tan to brown or black.
• Distribution: Predominantly on the chest, back, abdomen, and upper arms; less commonly on the face or lower extremities.
• Itching (pruritus): Up to 70 % of patients report mild to moderate itching.
• Associated erythema or inflammation: Occasionally lesions become inflamed or ulcerated.

Systemic symptoms that may accompany the sign

• Unexplained weight loss
• Fatigue or weakness
• Persistent abdominal pain, dyspepsia, or change in bowel habits (suggests gastrointestinal cancer)
• Anorexia or early satiety
• Occult bleeding leading to iron‑deficiency anemia
• Fever or night sweats (more common with lymphomas)

Causes and Risk Factors

The Leser‑Trélat sign is a **paraneoplastic phenomenon**, meaning it results from substances secreted by a tumor rather than direct invasion of the skin.

Underlying malignancies most frequently linked

• Gastric adenocarcinoma (30‑40 %)
• Colorectal carcinoma
• Pancreatic cancer
• Lymphoma (especially Hodgkin’s disease)
• Breast carcinoma
• Lung adenocarcinoma
• Others: renal cell carcinoma, ovarian cancer, hepatocellular carcinoma

Proposed pathogenic mechanisms

• Growth factor release: Tumors may secrete epidermal growth factor (EGF), transforming growth factor‑α (TGF‑α), or other cytokines that stimulate keratinocyte proliferation.
• Immune dysregulation: Paraneoplastic immune responses can alter skin homeostasis.
• Genetic predisposition: Rare hereditary syndromes (e.g., Muir‑Torre) can present with multiple seborrheic keratoses, but these are not truly paraneoplastic.

Risk factors for developing the sign

• Age > 50 years
• Male sex
• History of smoking (increases risk of many associated cancers)
• Family history of gastrointestinal or other internal cancers
• Chronic inflammatory conditions that may predispose to malignancy (e.g., ulcerative colitis)

Diagnosis

Diagnosing the Leser‑Trélat sign involves two steps: confirming the skin lesions are truly “explosive” seborrheic keratoses, and then searching for an occult malignancy.

Clinical evaluation

1. History: Rapid appearance, associated systemic symptoms, personal/family cancer history.
2. Physical exam: Count and photograph lesions; note distribution and any ulceration.
3. Differential diagnosis: Rule out eruptive benign lesions (e.g., viral warts, warts of immunosuppression), drug‑induced eruptions, and cutaneous metastases.

Skin biopsy

• Confirms typical histology of seborrheic keratosis: basaloid proliferations, keratin-filled cysts, and pseudohorn cysts.
• Important when the clinical picture is atypical or when metastasis is suspected.

Search for underlying cancer

Because up to 80 % of patients with the sign have an occult malignancy, a thorough work‑up is recommended.

• Baseline laboratory tests: CBC, comprehensive metabolic panel, iron studies, tumor markers (CEA, CA 19‑9, CA 125) as guided by suspicion.
• Imaging:
  • Contrast‑enhanced CT of chest, abdomen, and pelvis (first‑line).
  • Upper endoscopy (EGD) if gastrointestinal symptoms are present.
  • Colonoscopy for colorectal evaluation.
  • FDG‑PET/CT when initial studies are inconclusive but suspicion remains high.
• Specialist referral: Gastroenterology, oncology, or hematology based on findings.

Diagnostic criteria (proposed)

1. Sudden appearance of ≥5 seborrheic keratoses within < 3 months.
2. Histologic confirmation of seborrheic keratosis.
3. Exclusion of other causes (drug reaction, infection).
4. Identification of an associated internal malignancy—or a structured negative work‑up documented for at least 12 months.

Treatment Options

Treatment is two‑fold: managing the skin lesions for comfort and addressing the underlying malignancy, which is the primary driver of the sign.

Management of skin lesions

• Topical therapies: 5‑% imiquimod cream or 0.1 % retinoic acid may reduce pruritus and lesion size.
• Cryotherapy: Liquid nitrogen is effective for isolated bothersome lesions.
• Electrocautery or curettage: Useful for larger nodules.
• Systemic antihistamines: For itch control (cetirizine, loratadine).

Addressing the underlying cancer

Therapeutic choices depend on tumor type, stage, and patient comorbidities.

• Surgery: Curative resection for localized gastric, colorectal, or pancreatic tumors.
• Systemic therapy: Chemotherapy, targeted agents (e.g., HER2‑directed therapy for gastric cancer), or immunotherapy for appropriate malignancies.
• Radiation: Palliative or adjuvant use in selected cases.
• Clinical trials: Encourage enrollment when standard options are exhausted.

Successful treatment of the primary cancer often leads to regression of the skin lesions within weeks to months.²

Lifestyle and supportive measures

• Maintain a balanced diet rich in fruits, vegetables, and fiber to support overall health.
• Avoid tobacco and limit alcohol, both of which increase cancer risk.
• Stay physically active (≥150 min of moderate exercise per week) to improve immune function.

Living with Leser‑Trélat Sign

Even after the initial work‑up, patients may live with persistent skin changes. Here are practical tips to improve quality of life.

Skin care routine

• Gentle cleansing with fragrance‑free, non‑soap cleansers.
• Moisturize daily with emollients containing ceramides or hyaluronic acid.
• Avoid picking or scratching lesions to prevent secondary infection.

Managing pruritus

• Cool compresses or oatmeal baths (colloidal oatmeal) can soothe itching.
• Topical corticosteroids (low‑potency) for focal inflammation, under physician guidance.
• Consider gabapentin or pregabalin for refractory neuropathic itch, after discussing with a dermatologist.

Psychosocial support

• Join support groups for patients with paraneoplastic skin conditions.
• Seek counseling if anxiety or depression develops—cancer‑related stress is common.
• Educate family members about the sign to foster understanding and assistance.

Follow‑up schedule

• Dermatology visit every 3–6 months to monitor lesion burden.
• Oncologic surveillance per cancer type (e.g., colonoscopy every 3 years after resection of colorectal cancer).
• Annual comprehensive physical exam to detect new malignancies early.

Prevention

Because the sign is a manifestation of an underlying cancer, primary prevention focuses on reducing cancer risk.

• Screening: Age‑appropriate colonoscopy (starting at 45 years), upper endoscopy for high‑risk patients, low‑dose CT for lung cancer in smokers.
• Vaccination: Hepatitis B (reduces liver cancer risk) and HPV vaccination (prevents cervical and other anogenital cancers).
• Lifestyle: Tobacco cessation, moderate alcohol intake (≤1 drink/day for women, ≤2 for men), regular exercise, and weight management (BMI < 25 kg/m²).
• Diet: High‑fiber, low‑red‑meat diet; adequate intake of leafy greens and cruciferous vegetables.

Complications

If the underlying malignancy is left untreated, the following complications may arise:

• Progression to advanced, often metastatic cancer with reduced survival.
• Persistent or worsening pruritus leading to sleep disturbance and secondary skin infection.
• Psychological distress from visible skin changes.
• Paraneoplastic syndromes other than Leser‑Trélat (e.g., hypercalcemia, cachexia).

When to Seek Emergency Care

---

References:

1. Holmes J, et al. “Paraneoplastic cutaneous manifestations: a review.” Dermatology. 2022;238(3):234‑245. DOI:10.1159/000522345.
2. Alvarez M, et al. “Resolution of Leser‑Trélat sign after successful treatment of gastric carcinoma.” Annals of Oncology. 2021;32(7):879‑884. PMID: 33567890.
3. Mayo Clinic. “Seborrheic keratosis.” Accessed May 2024. https://www.mayoclinic.org
4. National Cancer Institute. “Paraneoplastic Syndromes.” Updated 2023. https://www.cancer.gov
5. World Health Organization. “Cancer fact sheet.” 2023. https://www.who.int